1. How long does the MSCC Protocol last?
The MSCC Protocol recommends a duration of approximately 12 weeks, regardless of cancer type. This timeframe is based on preclinical models and clinical observations showing measurable effects within that window (Martinez et al., 2024).
Always consult a licensed healthcare provider before beginning any protocol or supplement.

2. Can I take the protocol while undergoing chemotherapy?
The MSCC Protocol does not provide specific guidance regarding compatibility with chemotherapy. As some components may interact with conventional treatments, medical oversight is essential.

However:

• High-dose IV Vitamin C has shown variable effects—some studies report enhanced chemosensitivity and reduced toxicity (Ma et al., 2014; Verrax & Calderon, 2009), while others caution it may interfere with ROS-dependent drugs (Heaney et al., 2008).

• Fasting has demonstrated tumor-sensitizing effects and reduced side effects in small human trials (Safdie et al., 2009; de Groot et al., 2020).

• Mebendazole has shown synergy with vincristine and temozolomide in preclinical models (Bai et al., 2011; Doudican et al., 2008).

• Fenbendazole demonstrated additive effects in cell-line models, though human data are lacking (Dogra et al., 2018; Gao et al., 2023).

• Ivermectin has exhibited chemosensitizing properties in preclinical cancer studies (Juarez et al., 2020; Heidary et al., 2011).

Always consult a licensed healthcare provider before combining therapies.

3. Can I take the protocol while undergoing immunotherapy?
The protocol does not address immunotherapy interactions directly. Given the immune-modulating nature of several components (e.g., Vitamin D, fasting), a healthcare provider should evaluate any potential overlap.

However:

• Vitamin D may improve immune checkpoint therapy responses in certain cancer settings (Chandler et al., 2020).

• Fasting and ketogenic diets have shown immune enhancement in animal models via autophagy and T-cell activation (De Francesco et al., 2018; Zhang et al., 2020).

• Mebendazole has been observed to stimulate anti-tumor immune responses through modulation of dendritic and T-cell activity (Pinto et al., 2015).

• Ivermectin may enhance checkpoint blockade by reprogramming tumor-associated macrophages and activating cytotoxic immunity (Li et al., 2021).

Always consult a licensed healthcare provider before combining therapies.

4. Can I take the protocol while undergoing radiation therapy?
No specific mention of radiation therapy compatibility is made in the MSCC Protocol. Some elements like HBOT and fasting have theoretical synergy, but professional evaluation is required (Poff et al., 2015).

However:

• HBOT has been studied for its ability to improve oxygenation and enhance radiosensitivity (Hadanny et al., 2022).

• Fasting has shown to protect normal tissue and increase radiation sensitivity of tumor cells in preclinical models (Nencioni et al., 2018).

• Mebendazole has demonstrated synergy with ionizing radiation in glioblastoma models (Bai et al., 2011).

• Fenbendazole has shown radiosensitizing effects via ROS generation and microtubule destabilization in vitro (Dogra et al., 2018).

Always consult a licensed healthcare provider before combining therapies.

5. Can I start parts of the protocol without having all components?

Yes. The authors acknowledge that not all components may be accessible and suggest that partial or staged implementation still aligns with the protocol’s educational goals (Martinez et al., 2024).
Always consult a licensed healthcare provider before making changes to your regimen.

6. What are the possible side effects from the components in the protocol?

Potential side effects include hypoglycemia from fasting, electrolyte imbalances on ketogenic diets, gastrointestinal discomfort from zinc, and drug interactions from repurposed agents like ivermectin or mebendazole (Guzzo et al., 2002; Hoppe et al., 2021).
Always consult a licensed healthcare provider for risk assessment.

7. Which organs can the protocol stress if I have an existing disease or dysfunction?

The protocol may pose risks to the liver (e.g., with mebendazole), kidneys (e.g., with high-dose Vitamin C), and lungs (e.g., with HBOT in COPD) (Riordan et al., 2000; Martinez et al., 2024). People with pre-existing organ dysfunction should use caution.
Always consult a licensed healthcare provider before beginning any protocol.

8. What is the overall safety profile of the protocol?

Most components have favorable safety profiles at suggested doses, based on long-term human use in other contexts (e.g., ivermectin, vitamin C, zinc). However, therapeutic application requires monitoring to manage risks and interactions (Gonzalez et al., 2002; de Castro et al., 2020).
Always consult a licensed healthcare provider before use.

9. Can I take the supplement components in pill form if I don’t have access to IV therapies?

The protocol notes that oral forms of some agents (e.g., Vitamin C, zinc, vitamin D) are more accessible but may not achieve the same pharmacologic effects as IV formulations (Gonzalez et al., 2002). Still, partial use is considered educationally valuable.
Always consult a licensed healthcare provider to tailor supplementation.

10. Is the MSCC Protocol designed to cure cancer?

No. The protocol is presented as an educational model, not a curative or prescriptive treatment. It is meant to explore metabolic strategies for supporting cancer biology understanding (Martinez et al., 2024).
Always consult a licensed healthcare provider for treatment planning.

11. Do I need a prescription for any part of the protocol?

Yes. Several components—such as ivermectin, mebendazole, and HBOT—typically require a prescription or medical supervision. Nutrients like vitamin D or zinc may be over-the-counter, but therapeutic use still warrants guidance.
Always consult a licensed healthcare provider before use.

12. Should I be medically monitored while on the protocol?

Yes. The protocol encourages routine lab testing and professional oversight, especially for serum levels of Vitamin D and zinc, blood glucose, and liver/kidney function (Martinez et al., 2024).
Always consult a licensed healthcare provider for ongoing monitoring.